For example, blocking the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) signaling pathways has remarkably improved the effectiveness of immunotherapy against many cancer types [9,10,11]. The gene discussed is CTLA4; the disease is cancer.